The U.S. Court of Appeals for the Second Circuit on Monday upheld the dismissal of a lawsuit accusing several companies of violating antitrust laws by using “reverse” settlement payments to delay the market entry of a high-blood-pressure drug’s generic versions.

The court, for its first time, clarified a 2013 U.S. Supreme Court ruling that such deals are sometimes illegal if they are large and “unjustified.”